10-K · February 26, 2026
Repligen reported a recovery in profitability through 2025 with Q4 revenue of $197,913,000 and improving margins (Q4 2025 gross margin 52.5%, operating margin 9.0%) after a weak Q4 2024. The company is executing a…
Earnings analysis · 10-Q
RGEN earnings analysis
Filed May 6, 2026 · Our reading of the company's report
The latest report
Repligen's Q1 2026 results showed a strong performance with revenue of $194.3 million, marking a 14.8% YoY increase, and an EPS of $0.48, surpassing estimates of $0.38. The company's growth was driven by robust product…
Read full summary
Repligen's Q1 2026 results showed a strong performance with revenue of $194.3 million, marking a 14.8% YoY increase, and an EPS of $0.48, surpassing estimates of $0.38. The company's growth was driven by robust product sales across segments, particularly in the chromatography and analytics sectors, demonstrating effective market penetration and operational efficiency.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.48
- Gross margin
- 55.7%
What stood out
-
Revenue Growth of 14.8% YoY
Q1 2026 revenue reached $194.25 million, up from $169.17 million in Q1 2025.
-
EPS Surpasses Expectations
Repligen reported an EPS of $0.48, beating estimates of $0.38 and increasing from $0.10 in Q1 2025.
-
Improved Gross Margin
Gross margin improved to 55.7%, up from 54.0% YoY, due to favorable sales mix and improved efficiency.
-
Significant Revenue Contribution from Acquisitions
Revenue from the 908 Devices PAT Portfolio contributed $2.4 million.
-
Positive Operating Cash Flow
Operating cash flow for Q1 2026 increased to $28.3 million, up from $15.0 million in Q1 2025.
-
Increase in Liquidity
Cash and cash equivalents rose to $582.65 million from $566.02 million at the end of 2025.
What to watch
-
Loss on Sale of Business
Repligen recognized a significant loss of $13.8 million from the sale of Polymem S.A.S.
-
Increased Interest Expense
Interest expense rose to $5.58 million from $5.25 million, reflecting higher debt costs.
-
Material Weaknesses in Internal Control
The company reported ongoing material weaknesses in internal control over financial reporting.
Management's outlook
Management expects 2026 revenue between $803 million and $833 million and EPS between $1.97 and $2.05, with a focus on continued product innovation.
Earlier filings 4
10-Q · August 7, 2025
Repligen reported a strong Q2 2025 quarter with revenue of $182,366,000 (Q2 2024: $158,839,000), driving operating income of $13,896,000 (Q2 2024: $5,469,000) and diluted EPS of $0.26 (Q2 2024: $0.10). Management…
10-Q · April 29, 2025
Repligen reported a stronger Q1 2025 with revenue rising to $169.172M from $153.182M a year ago (+$15.99M, +10.4%), gross margin expanding to ~53.7% (COGS $78.415M) and operating income rising to $6.578M (3.9% op…
10-K · March 14, 2025
Repligen positions itself as a diversified bioprocessing platform selling consumables, systems and analytics across four franchises (Filtration; Chromatography; Process Analytics; Proteins) and is shifting from…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.